Immunocore Hldgs shares details from their earnings call for the second quarter of 2026.

Oct 5, 2026, 9:15 AM ETResultsRead the original at Benzinga

Good for IMCR

Immunocore's Kimmtrak sales grew in the first half, and it had $880 million in cash reserves with a quarterly loss under $1 million. Management expects slower sales growth, and $6 million of Q2 distributor inventory will weigh on Q3, but sales growth, cash, and advancing trials support a stronger outlook.

IMCR · Immunocore Hldgs

AI read · Good for IMCR

The AI's read

Kimmtrak is bringing in growing sales, and five-year patient data gives the company a strong result to build on. Immunocore also has substantial cash and several late-stage trials underway. Sales growth may cool. Management expects slower growth and said distributor inventory added in Q2 will weigh on Q3 sales. Those concerns temper the story, but current sales, cash, and advancing trials make the positives stronger.

Get alerts for IMCR

Follow Immunocore Hldgs (IMCR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IMCR

Free on the App Store and Google Play, or on the web.